Retatrutide

Retatrutide is an investigational molecule that acts at three receptors: GLP-1, GIP, and glucagon. That third target distinguishes it from semaglutide, which acts at one, and tirzepatide, which acts at two.

Published phase 2 results reported weight reductions larger than those seen with earlier agents in this class, which is why it is discussed heavily despite not being approved. It remains investigational, and its full trial programme is not complete. Material sold under this name outside a trial is not the investigational drug and has no assurance of identity or purity.

Obesity, type 2 diabetes and metabolic disease, in an active and incomplete clinical trial programme.

Published trials report gastrointestinal effects, principally nausea and vomiting, as the most common category, consistent with this drug class. The complete safety profile awaits the full trial programme.

An injectable formulation within the clinical trial setting. Material outside that setting is not a regulated pharmaceutical product.